DUBLIN–(BUSINESS WIRE)–The “Digital Advertising Developments in Human Immunodeficiency Virus (HIV)” report has been added to ResearchAndMarkets.com’s providing.
Gilead’s Biktarvy.com achieved the very best visitors throughout branded HIV affected person websites within the US from April 2021 to March 2022, with about 3,800,000 visits, adopted by ViiV’s Dovato.com and Gilead’s Descovy.com. The best proportion of visitors to those websites originated from direct sources, adopted by referrals. Web sites for a number of manufacturers, together with Descovy, Cabenuva, Truvada, and Pifeltro, had related ranges of excessive direct visitors (53-57%), whereas Janssen’s Symtuza.com had the bottom (34%).
For affected person branded websites, Gilead spent probably the most on DDA for Biktarvy.com at $20.5 million, adopted by Gilead’s Descovy.com at $3.6 million and ViiV’s Dovato.com at $2.3 million. Descovy.com was supported by probably the most paid key phrases at roughly 10,200 key phrases, adopted by Biktarvy.com at about 5,900 key phrases.
For branded HCP websites within the US, Gilead’s Descovyhcp.com had the very best variety of visits at roughly 250,000 visits, adopted by Gilead’s Biktarvyhcp.com (198,500 visits) and ViiV’s Dovatohcp.com (184,000 visits). The best proportion of visitors these websites originated from direct and natural sources. ViiV’s Rukobiahcp.com and Dovatohcp.com had the very best proportion of visitors from direct searches (66% and 61%, respectively). Gilead spent probably the most on DDA for Biktarvyhcp.com at roughly $212,000, adopted by its Descovyhcp.com at roughly $67,000.
Between April 2021 and March 2022, the highest 20 social media HIV posts by interplay from pharma have been from Gilead COMPASS Initiative Twitter and Instagram, ViiV Healthcare’s Instagram, and Gilead Science’s Twitter. Gilead’s HIV Solutions is the one app detected from pharma is the US and had an estimated 730 downloads in 2021.
Most branded web sites in EUCAN are in Canada and are patient-directed. Few generated notable visitors between April 2021 and March 2022. Gilead’s Bitarvy.ca and Descovy.ca achieved the very best visitors, with about 52,000 visits and 27,000 visits, respectively.
Between April 2021 and March 2022, many of the prime 20 social media HIV posts by interplay in EUCAN from pharma have been from MSD Europe’s Twitter account. No HIV apps from pharma with notable downloads have been detected in EUCAN.
Scope
This report assesses key digital advertising metrics of pharma property in human immunodeficiency virus (HIV), together with branded web sites for sufferers and healthcare professionals (HCPs), cell apps, and social media accounts
Metrics embody web site visitors quantity, engagement, and supply, digital show promoting (DDA), paid SEO (search engine optimization), cell app downloads, and social media submit interplay
International locations embody the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN)
Causes to Purchase
Perceive the digital advertising aggressive panorama in HIV, with a view of main affected person and HCP branded property throughout completely different areas
See what techniques pharma corporations are utilizing to drive visitors to their HIV branded property for affected person and HCPs, reminiscent of DDA and paid search engine optimization
Perceive what sources of web site visitors are producing probably the most visits to those property, reminiscent of paid search engine optimization, social media, or natural searches
Examine prime branded property for sufferers by how they handle and assist completely different affected person wants
See what pharma social media accounts in HIV are probably the most lively and attaining probably the most engagement
See main cell app choices in HIV from pharma throughout completely different areas
Key Subjects Lined:
Govt Abstract
US Affected person Branded Web sites
US HCP Branded Web sites
US Digital Show Promoting and Search Engine Optimization
US Cell Apps and Social Media
EUCAN Branded Web sites
EUCAN Cell Apps and Social Media
Appendix
Methodology
Concerning the Authors
Contact the Writer
For extra details about this report go to https://www.researchandmarkets.com/r/95ajx3